Legal status · United States
Is MET-233i legal in the United States?
No. MET-233i is not approved for any medical use in the United States; its classification is "Investigational, not approved". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. Human evidence to date: Preliminary.
MET-233i in the United States at a glance
| Classification | Investigational, not approved |
|---|---|
| FDA approval status | Investigational; Phase 2 (combination) |
| Evidence level | Preliminary (research strength: Preliminary) |
| Reviewed | Sep 2026 |
Classification and note come from the MET-233i profile, checked against U.S. Food and Drug Administration (FDA) listings at the reviewed date.
What this means
- 01
MET-233i is being studied in registered clinical trials but has not received FDA marketing approval in the United States.
- 02
Lawful human access is limited to trial participation or a formal early-access scheme where one exists; there is no pharmacy product to prescribe.
- 03
Vials sold online "for research use only" are not trial material, and that label does not make human use lawful.
What MET-233i is
Pfizer's monthly amylin analog (from Metsera) with a 19-day half-life, being co-formulated with berobenatide into a once-monthly GLP-1 plus amylin combination.
MET-233i shares the albumin-binding platform used by berobenatide. 4% placebo-subtracted weight loss by day 36 as a monotherapy, and Pfizer's 2026 pipeline lists the combination with berobenatide in Phase 2.
Mechanism: Ultra-long-acting amylin receptor agonism, designed for monthly dosing alone or with a GLP-1 agonist.
Regulatory history: Investigational; Phase 2 (combination)
How FDA treats this kind of product
Approves prescription drugs by indication and polices unapproved products, including peptides sold online. Compounding pharmacies may prepare some compounds under a prescription when the FDA places them on a permitted bulk-substances category.
The classification above is the The Longevity Archive reading of U.S. Food and Drug Administration listings for MET-233i at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
MET-233i in other countries
Frequently asked questions
Is MET-233i legal in the United States?
No. MET-233i is not approved for any medical use in the United States; its classification is "Investigational, not approved". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. Human evidence to date: Preliminary.
Can I buy MET-233i in the United States?
No approved product exists to buy. In the United States MET-233i is classified as "Investigational, not approved", so there is no licensed pharmacy product. Vendors selling it "for research use only" are not selling it for human use, and that label does not change its legal status. This site does not list or recommend vendors.
Is MET-233i FDA approved?
No. FDA status: Investigational; Phase 2 (combination). Current US classification: "Investigational, not approved". Evidence level: Preliminary.
Related compounds in the United States
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for MET-233i live on its compound profile.
MET-233i profileThis page is general information about the regulatory status of MET-233i in the United States, current as of Sep 2026. It is not legal advice, and classifications change; check U.S. Food and Drug Administration directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.